Company Logo

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapy treatment for depression and medication are not effective for a lot of patients suffering from depression. A customized treatment may be the solution.

Cue is a digital intervention platform that transforms passively acquired sensor data from smartphones into customized micro-interventions designed to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct features that are able to change mood as time passes.

Predictors of Mood

depression treatment Without medicines is a leading cause of mental illness in the world.1 Yet the majority of people affected receive treatment. To improve outcomes, doctors must be able to recognize and treat patients with the highest probability of responding to particular treatments.

Personalized depression treatment is one method to achieve this. By using sensors ect for treatment resistant depression mobile phones as well as an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from the treatments they receive. Two grants totaling more than $10 million will be used to determine the biological and behavioral predictors of response.

To date, the majority of research into predictors of depression treatment effectiveness has focused on sociodemographic and clinical characteristics. These include demographics such as gender, age and education, as well as clinical characteristics like symptom severity, comorbidities and biological markers.

Few studies have used longitudinal data to predict mood of individuals. Few studies also take into account the fact that moods can be very different between individuals. Therefore, it is essential to create methods that allow the identification of the individual differences in mood predictors and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to detect patterns of behaviour and emotions that are unique to each person.

The team also devised an algorithm for machine learning to identify dynamic predictors of the mood of each person's depression. The algorithm blends the individual characteristics to create an individual "digital genotype" for each participant.

This digital phenotype was associated with CAT DI scores which is a psychometrically validated symptom severity scale. The correlation was weak however (Pearson r = 0,08, BH adjusted P-value 3.55 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is one of the leading causes of disability1, but it is often underdiagnosed and undertreated2. In addition an absence of effective treatments and stigmatization associated with depressive disorders stop many people from seeking help.

To assist in individualized treatment, it is essential to identify the factors that predict symptoms. However, current prediction methods depend on the clinical interview which has poor reliability and only detects a limited number of symptoms that are associated with depression.2

Machine learning can improve the accuracy of the diagnosis and treatment of depression by combining continuous digital behavioral patterns gathered from sensors on smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can provide continuous, high-resolution measurements and capture a wide variety of unique behaviors and activity patterns that are difficult to record through interviews.

The study involved University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA inpatient depression treatment centers Grand Challenge. Participants were referred to online support or to clinical treatment according to the severity of their depression. Patients with a CAT DI score of 35 or 65 were assigned online support via the help of a peer coach. those with a score of 75 patients were referred to in-person clinics for psychotherapy.

Participants were asked a series of questions at the beginning of the study about their psychosocial and demographic characteristics as well as their socioeconomic status. These included sex, age, education, work, and financial status; whether they were divorced, married, or single; current suicidal ideas, intent, or attempts; and the frequency at that they consumed alcohol. Participants also rated their degree of depression treatment online symptom severity on a scale of 0-100 using the CAT-DI. The CAT-DI assessment was performed every two weeks for those who received online support and weekly for those who received in-person assistance.

Predictors of Treatment Response

Research is focused on individualized depression treatment. Many studies are focused on finding predictors, which can aid clinicians in identifying the most effective medications to treat each patient. Particularly, pharmacogenetics can identify genetic variants that influence how the body's metabolism reacts to antidepressants. This allows doctors select medications that will likely work best for every patient, minimizing time and effort spent on trial-and error treatments and avoiding any side consequences.

Another option is to build prediction models that combine clinical data and neural imaging data. These models can then be used to identify the best combination of variables that is predictors of a specific outcome, like whether or not a particular medication will improve mood and symptoms. These models can be used to determine a patient's response to treatment that is already in place and help doctors maximize the effectiveness of the treatment currently being administered.

A new generation employs machine learning techniques such as algorithms for classification and supervised learning such as regularized logistic regression, and tree-based methods to integrate the effects of several variables and increase the accuracy of predictions. These models have been shown to be useful in predicting the outcome of treatment like the response to antidepressants. These methods are becoming popular in psychiatry, and it is likely that they will become the standard for future clinical practice.

In addition to the ML-based prediction models The study of the mechanisms that cause depression continues. Recent findings suggest that depression is connected to dysfunctions in specific neural networks. This theory suggests that a individualized treatment for depression will be based upon targeted therapies that restore normal function to these circuits.

Internet-delivered interventions can be a way to achieve this. They can provide a more tailored and individualized experience for patients. One study found that an internet-based program improved symptoms and provided a better quality life for MDD patients. Furthermore, a randomized controlled study of a personalised approach to depression treatment showed an improvement in symptoms and fewer adverse effects in a significant proportion of participants.

Predictors of adverse effects

In the treatment of depression, the biggest challenge is predicting and determining the antidepressant that will cause very little or no negative side effects. Many patients are prescribed a variety of medications before settling on a treatment that is safe and effective. Pharmacogenetics offers a new and exciting method to choose antidepressant drugs that are more effective and specific.

Several predictors may be used to determine which antidepressant to prescribe, including genetic variants, patient phenotypes (e.g. sexual orientation, gender or ethnicity) and comorbidities. To determine the most effective treatment for depression reliable and reliable predictors for a particular treatment, random controlled trials with larger numbers of participants will be required. This is because it could be more difficult to detect the effects of moderators or interactions in trials that comprise only one episode per participant rather than multiple episodes over a long period of time.

Furthermore the prediction of a patient's response will likely require information on the severity of symptoms, comorbidities and the patient's own perception of the effectiveness and tolerability. At present, only a handful of easily identifiable sociodemographic variables and clinical variables are reliable in predicting the response to MDD. These include gender, age, race/ethnicity, BMI, SES and the presence of alexithymia.

There are many challenges to overcome in the application of pharmacogenetics in the treatment of depression. First, it is essential to have a clear understanding and definition of the genetic mechanisms that cause depression, as well as an understanding of a reliable predictor of treatment response. Ethics like privacy, and the ethical use of genetic information must also be considered. Pharmacogenetics can be able to, over the long term help reduce stigma around mental health treatments and improve the quality of treatment. As with any psychiatric approach it is crucial to take your time and carefully implement the plan. At present, it's recommended to provide patients with a variety of medications for depression that are effective and urge patients to openly talk with their physicians.